Pharmaceutical research provider Tigermed co-led a round sized at nearly $71m for the cancer drug developer, which was spun off from Eddingpharm.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Cancer and autoimmune disease drug developer Clover Biopharmaceuticals has now raised in excess of $100m altogether, Jinrong Group backing its latest round.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Temasek has led a $220m funding round for PharmEasy, whose existing shareholders include Ascent Health and Wellness, Medi Assist and Manipal Education and Medical Group.

KU Leuven and Wellcome Trust will pilot a tech transfer scheme equipping early-stage scientific research with mentoring, prototyping and regulatory assistance.

USF and Florida Funders have tapped angel investment for a seed fund set to nurture research from Florida's public universities and the wider state ecosystem.

Russell Greig, once president of GlaxoSmithKline subsidiary SR One, has taken the chairman position at drug developer BiomX, nine years after leaving the unit.

JMDC, Gene Techno Science, Astellas Venture Management and Nissay Capital have contributed to a $25.8m round for Keio University's heart failure treatment developer.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.